Oryzon Genomics SA (ORY) - Total Liabilities

Latest as of December 2025: €26.68 Million EUR ≈ $31.19 Million USD

Based on the latest financial reports, Oryzon Genomics SA (ORY) has total liabilities worth €26.68 Million EUR (≈ $31.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Oryzon Genomics SA - Total Liabilities Trend (2011–2025)

This chart illustrates how Oryzon Genomics SA's total liabilities have evolved over time, based on quarterly financial data. See ORY working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Oryzon Genomics SA Competitors by Total Liabilities

The table below lists competitors of Oryzon Genomics SA ranked by their total liabilities.

Company	Country	Total Liabilities
Even Construtora e Incorporadora S.A SA:EVEN3	Brazil	R$3.02 Billion
Taaleri Oyj HE:TAALA	Finland	€84.96 Million
Orge Enerji Elektrik Taahhut AS IS:ORGE	Turkey	TL1.77 Billion
Akmerkez Gayrimenkul Yatirim Ortakligi AS IS:AKMGY	Turkey	TL1.88 Billion
EIH Associated Hotels Limited NSE:EIHAHOTELS	India	Rs1.17 Billion
GNCO Co. Ltd KQ:065060	Korea	₩122.63 Billion
The Gold Bond Group Ltd TA:GOLD	Israel	ILA249.93 Million
EBEST Investment & Securities Co. Ltd KQ:078020	Korea	₩9.51 Trillion

Liability Composition Analysis (2011–2025)

This chart breaks down Oryzon Genomics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORY stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.25	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oryzon Genomics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oryzon Genomics SA (2011–2025)

The table below shows the annual total liabilities of Oryzon Genomics SA from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	€26.68 Million ≈ $31.19 Million	+23.07%
2024-12-31	€21.67 Million ≈ $25.34 Million	-13.74%
2023-12-31	€25.13 Million ≈ $29.37 Million	-19.28%
2022-12-31	€31.13 Million ≈ $36.39 Million	+29.04%
2021-12-31	€24.12 Million ≈ $28.20 Million	+32.72%
2020-12-31	€18.18 Million ≈ $21.25 Million	+22797.11%
2019-12-31	€79.38K ≈ $92.80K	-99.64%
2018-12-31	€22.33 Million ≈ $26.10 Million	-16.11%
2017-12-31	€26.61 Million ≈ $31.11 Million	-1.49%
2016-12-31	€27.02 Million ≈ $31.58 Million	+105.63%
2015-12-31	€13.14 Million ≈ $15.36 Million	+8.00%
2014-12-31	€12.16 Million ≈ $14.22 Million	-13.32%
2013-12-31	€14.04 Million ≈ $16.41 Million	+13.63%
2012-12-31	€12.35 Million ≈ $14.44 Million	-0.81%
2011-12-31	€12.45 Million ≈ $14.56 Million	--

About Oryzon Genomics SA

MC:ORY Spain Biotechnology

Market Cap

$286.00 Million

€244.63 Million EUR

Market Cap Rank

#16348 Global

#105 in Spain

Share Price

€3.16

Change (1 day)

+0.64%

52-Week Range

€2.57 - €3.82

All Time High

€5.14